ACTGAcacia Research Corporation
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~23% a year FCF growth. The price demands less than its three-year revenue growth of 75% a year, expectations look modest.
Expensive vs its own history: P/E 17.0 vs a 8.7 median over 16 quarters (+96% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ACTG's price assumes
Acacia Research Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.16× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.4%
Free cash flow yield · Industrials median 4.2%
- Growth the price implies
- +23%
Growth the price implies · The price pays for +23% free cash flow growth a year for a decade; revenue has grown +75% a year over the last three.
- Price / book
- 0.88
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 0.88
- EV / EBIToperating margin −7.0%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 1.21
- Free cash flow, trailing twelve months
- $5.9M
- Market capitalisation
- $424M
- 3-year revenue growth
- +75%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.